Values First Advisors Inc. Buys 7,148 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Values First Advisors Inc. boosted its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 17.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 48,068 shares of the company’s stock after buying an additional 7,148 shares during the quarter. Values First Advisors Inc.’s holdings in Zentalis Pharmaceuticals were worth $728,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. grew its position in Zentalis Pharmaceuticals by 10.2% during the second quarter. Ameritas Investment Partners Inc. now owns 4,057 shares of the company’s stock valued at $114,000 after buying an additional 376 shares during the period. US Bancorp DE grew its position in Zentalis Pharmaceuticals by 88.7% during the second quarter. US Bancorp DE now owns 887 shares of the company’s stock valued at $25,000 after buying an additional 417 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Zentalis Pharmaceuticals by 1.9% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,404 shares of the company’s stock valued at $857,000 after buying an additional 569 shares during the period. Principal Financial Group Inc. boosted its position in shares of Zentalis Pharmaceuticals by 4.5% in the second quarter. Principal Financial Group Inc. now owns 14,081 shares of the company’s stock worth $397,000 after purchasing an additional 603 shares during the period. Finally, MetLife Investment Management LLC boosted its position in shares of Zentalis Pharmaceuticals by 2.4% in the second quarter. MetLife Investment Management LLC now owns 25,544 shares of the company’s stock worth $721,000 after purchasing an additional 608 shares during the period.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock traded up $0.57 during mid-day trading on Friday, hitting $15.76. The company had a trading volume of 577,810 shares, compared to its average volume of 931,754. Zentalis Pharmaceuticals, Inc. has a 52-week low of $9.56 and a 52-week high of $31.46. The stock’s 50 day moving average price is $13.46 and its 200-day moving average price is $14.99. The company has a market capitalization of $1.12 billion, a P/E ratio of -3.47 and a beta of 1.72.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.09. On average, equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Insider Activity at Zentalis Pharmaceuticals

In related news, CFO Melissa B. Epperly sold 2,573 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $11.44, for a total transaction of $29,435.12. Following the sale, the chief financial officer now owns 451,449 shares of the company’s stock, valued at $5,164,576.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $46.00 price target on shares of Zentalis Pharmaceuticals in a research report on Wednesday, February 28th. Wedbush upped their price target on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 28th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.57.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.